Analysis of clinical samples has revealed reduced KMT2C expression in larynx carcinoma [7], pancreatic ductal adenocarcinoma [8], and gastric cancer [9], and silencing of KMT2C due to promoter DNA hypermethylation has been observed in urothelial cancer [10]. Here, KMT2C is linked to gastric cancer.